Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDR1 diplotypes as prognostic markers in multiple myeloma.

Pharmacogenetics and genomics - 1 May 2008

Maggini Valentina, Buda Gabriele, Martino Alessandro, Presciuttini Silvano, Galimberti Sara, Orciuolo Enrico, Barale Roberto, Petrini Mario, Rossi Anna Maria

Abstract excerpt

OBJECTIVE: The aim of this study was to evaluate the effect of diplotypes of MDR1 polymorphisms at positions 2677 and 3435 on the clinical outcome of multiple myeloma, in terms of response to the therapy and overall survival (OS). METHODS: G2677T/A SNP was analysed by RFLP-PCR assay on 110 patients, treated with dexamethasone, doxorubicin (adryamicin) and vincristine regimen, followed by autologous stem cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to Genetic Markers

Share to Linkage Disequilibrium

Share to Multiple Myeloma

Share to Prognosis

Share to Survival Analysis

Source

Identifiers

PMID: 18408561
DOI: 10.1097/FPC.0b013e3282f82297

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDR1 diplotypes as prognostic markers in multiple myeloma.PMID 18408561Read ↗

MDR1 polymorphism influences the outcome of multiple myeloma patients.Semantic proximity Read ↗

MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma.Semantic proximity Read ↗

MDR1 polymorphisms affect the outcome of Chinese multiple myeloma patients.Semantic proximity Read ↗

Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma.Semantic proximity Read ↗

Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia.Semantic proximity Read ↗

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens.Semantic proximity Read ↗

MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis.Semantic proximity Read ↗

Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide.Semantic proximity Read ↗

Association of MDR1 single-nucleotide polymorphisms and haplotype variants with multiple myeloma in Chinese Jiangsu Han population.Semantic proximity Read ↗

Effects of TNFα, NOS3, MDR1 Gene Polymorphisms on Clinical Parameters, Prognosis and Survival of Multiple Myeloma Cases.Semantic proximity Read ↗

Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugsSemantic proximity Read ↗

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.